The global pharmacovigilance market may be an $8 billion industry, but it’s powered by outdated tech and painfully manual processes.
Graph AI wants to change that with a unified, intelligent platform that brings patient safety into the modern age.
Why drug safety is stuck in the past
The role of pharma companies doesn’t end with launching the medicine. They have to collect feedback and ensure the medicine is actually giving the intended results without any side effects. How do companies do that?
By pharmacovigilance—basically, collecting and analyzing side-effect reports from doctors, patients, and clinical trials.
But this system is slow, fragmented, and extremely manual. It’s like solving a massive, constantly changing jigsaw puzzle where the pieces are scattered across different rooms.
Safety teams juggle spreadsheets, disconnected tools, and mountains of paperwork. Important signals can get lost. Insights come too late.
This inefficiency can put patients at risk.
Graph AI is stepping in to fix this.
So, what does Graph AI actually do?
In simple terms, Graph AI provides a smart, all-in-one software platform that automates and modernises the entire drug-safety workflow. Think of it as a central nervous system for patient safety.
Its flagship product, the Graph Safety suite, is the first generative-AI platform built specifically to unify every part of patient safety.
Think of it as a single, intelligent system that manages the entire safety process, from collecting initial data all the way to generating regulatory reports.
Here’s what it does:
Automates the boring paperwork
Its intake module automatically collects and sorts through safety reports from across the world, and organizes them into a single, clear case file. This replaces hours of manual data entry.
Finds safety signal faster
Its advanced AI looks at all this unified data to proactively detect potential new safety risks (called “signal detection”) that a human might miss while buried in piles of paperwork.
Handles global compliance
It automatically generates the complex regulatory reports that drug companies must submit to regulators like the FDA, helping them stay error-free and on schedule.
GraphX engine
The magic behind it is its proprietary engine called the GraphX platform. It is a sophisticated “intelligence layer” that brings together disconnected data, workflows, and regulatory requirements into one seamless system.
GraphX’s unique, GenAI-native design understands complex relationships across datasets, spots patterns, and generates insights that would otherwise remain hidden.
A key advantage is that the companies can securely fine-tune the AI using their own private safety data, making the results more accurate, trustworthy, and compliant.
The founding story: Fixing a broken system
Graph AI was founded in 2024 in California by a team of seasoned tech and life-sciences professionals: Raghavendra Parvataraju, Vijay Ponukumati, Mohan Konyala, and Ashutosh Bordekar.
They’d all noticed the same thing: companies were relying on old systems that didn’t talk to each other. Safety teams were drowning in data silos, manual handoffs, and outdated tools.
So, they set out to build a unified AI-native platform that makes safety monitoring smarter, faster, and far more dependable.
This entire ethos is encapsulated in the company’s foundational formula:
Efficiency = Human ingenuity scaled by the exponential impact of GraphX.
The well-rounded founding team, Graph AI’s biggest strengths
Here’s what each founder brings to the table:
Raghavendra Parvataraju (CEO): A veteran leader with deep experience in enterprise IT, he’s responsible for building and scaling Graph AI’s global platform.
Vijay Ponukumati (CTO): Tech lead with strong engineering chops, bringing in-depth expertise to architect Graph AI’s core systems.
Mohan Konyala (CPO): Product visionary who has previously worked at companies like ServiceNow. He helps shape Graph Safety’s features to be both powerful and user-friendly.
Ashutosh Bordekar (CFO & COO): The financial and operational brain. He ensures the company stays on track financially while scaling teams and processes.
The founders pointed out in a joint statement,
“The life sciences industry continues to grapple with outdated technology, fragmented point solutions, data silos, and manual handoffs that hinder decision-making and elevate compliance risks.
At Graph AI, we’re addressing these challenges with a unified, AI-native safety platform that integrates context, compliance, and intelligence into a single seamless ecosystem.”
A strong vote of confidence: $3 Mn seed round
Last month, Graph AI raised $3 million in seed funding, led by Bessemer Venture Partners, one of the world’s most respected VC firms. A significant endorsement for Graph AI’s disruptive potential.
Bessemer backed the company for its rare mix of deep tech, enterprise experience, and clinical expertise—a combination they believe can reshape an entire industry.
The fresh capital is now fueling product development and market expansion.
Proven impact (already impressive)
Graph AI is transforming theory into tangible results. Early enterprise users of the Graph Safety platform are seeing:
- Up to 70% gains in operational efficiency.
- 90% faster regulatory reporting.
- Substantial cost savings.
All this while maintaining complete, end-to-end traceability, audit-readiness, and compliance.
Graph AI is built for the future of compliance
Graph AI is designing its platform with the FDA’s new Computer Software Assurance (CSA) model in mind—a modern, risk-based approach that replaces the old, cumbersome validation process.
As Graph Safety is GenAI-native, it’s naturally easier to validate under these new guidelines, making it far less risky for large pharma companies to adopt.
What’s next: Expanding beyond drug safety
The ambition extends far beyond drug safety. The company’s long-term 3xV roadmap aims to take the GraphX engine into new areas like:
- Cosmetovigilance (safety of cosmetics)
- Materiovigilance (safety of medical devices)
The ambitious vision is to build a safety ecosystem where every sector, from medicines to devices, is powered by intelligent, connected, AI-driven monitoring.
Graph AI is also ensuring its platform easily meets modern regulatory standards, making it less of a headache for big companies to adopt.
As Bessemer’s Nithin Kaimal puts it, competitive advantage is no longer about cheap labor—it’s about “intelligence arbitrage.”
-By Alkama Sohail and the AHT Team
